Rokt is a leading provider of e-commerce technology that enhances the customer buying experience by integrating marketing into the transaction moment. The company works with prominent brands like Live Nation, Groupon, and GoDaddy to deliver tailored advertising at critical points during the purchasing process. This approach enables e-commerce businesses to boost brand engagement, unlock new revenue streams, and improve overall customer experiences. Founded in Sydney, Rokt has expanded its operations globally, serving clients across various regions, including North America, Europe, and Asia. Its proprietary technology aims to connect advertisers with customers at opportune moments, facilitating effective upselling and cross-selling opportunities while keeping businesses competitive in the rapidly evolving e-commerce landscape.
Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.
Archaea Energy is an emerging leader in developing renewable natural gas (“RNG”) which is a sustainable decarbonizing solution for high-carbon emission processes and industries that are impossible or inefficient to electrify.
HYZON Motors Inc manufactures hydrogen-powered trucks and buses. It offers city and coach buses, medium duty trucks, and heavy duty trucks. The company was founded in 2020 and is based in Honeoye Falls, New York.
Markforged, founded in 2013 and based in Watertown, Massachusetts, specializes in designing and manufacturing advanced 3D printers that utilize materials such as carbon fiber, metal, fiberglass, nylon, and PLA filament. The company's printers are engineered to produce durable parts, tooling, fixtures, and functional prototypes suitable for industrial applications. Markforged also offers EIGER, its proprietary 3D printing software, which enhances the printing process. With a global workforce of approximately 300 employees, the company has attracted significant investment, totaling around $137 million. Markforged has garnered recognition for its innovative contributions to manufacturing, including being featured in Forbes' Next Billion-Dollar Startups list and ranking as one of the fastest-growing hardware companies in the United States according to Deloitte's Fast 500.
Payoneer Inc. operates a cross-border payments platform designed to facilitate global commerce by connecting businesses, professionals, countries, and currencies. Founded in 2005 and headquartered in New York, the company offers products such as the Global Payment Service, which provides users with local receiving accounts in the United States, European Union, and Japan, allowing for direct local bank transfers. Additionally, Payoneer enables users to receive payments from various integrated partners, including those in freelance, e-commerce, and online advertising sectors. The company also provides mass payout services that assist Indian companies in transferring funds internationally. Serving millions of users across over 200 countries, Payoneer is a trusted partner for numerous prominent corporations, making cross-border payments as straightforward as local transactions.
Perella Weinberg Partners is an independent, privately-owned financial services firm that provides corporate advisory and asset management services to clients around the world. The Firm has assembled a group of talented and experienced professionals recruited from a wide variety of leading global financial institutions.
Launched in 2006, the company is divided into two business units: corporate advisory, which provides services to decision makers in business and government, and asset management, which consists of investment vehicles catering to institutional investors.
Lendbuzz Funding, LLC offers car loans to expats and international students. The company does not require Social Security Number (SSN) and provides loans to all visa holders from all nationalities. Its customers include students, international professionals, and other young professionals that have an international credit file. The company provides access and manages its loans through an online platform and data-intensive scoring technology. Lendbuzz Funding, LLC was founded in 2015 and is based in Boston, Massachusetts.
Latch makes access easier for everyone at a modern building. The company specializes in manufacturing keyless entry security system giving property owners the ability to manage every door in a multi-family building. Moreover, residents can also give access to guests as well as service providers through time-limited access codes. Latch is headquartered in New York, New York, United States.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Billtrust develops a payment cycle management platform designed to automate every step in the invoice-to-cash process. Its platform accelerates cash flow by automating invoice delivery, invoice payment, and cash application for remarkable cost savings, ease-of-use, and improved customer satisfaction rates, enabling businesses and corporate clients to improve operational efficiency. The company was founded in 2001 and is headquartered in Lawrenceville, New Jersey.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing advanced precision oncology therapies for cancer treatment. Founded in 2020, the company aims to enhance the accessibility and effectiveness of precision medicine for cancer patients. Scorpion Therapeutics specializes in creating drugs in three primary areas: therapies targeting known oncogenes, agents for currently undruggable cancer targets, and innovative drugs for new targets. By integrating state-of-the-art technologies in target discovery, medicinal chemistry, and translational medicine, the company is committed to delivering next-generation precision oncology solutions. Its experienced leadership team is dedicated to employing a tailored approach to efficiently advance the field of precision cancer treatment.
Cityblock Health is a healthcare provider focused on delivering primary care, behavioral health, and virtual care services to lower-income communities. Established in 2017 and based in Brooklyn, New York, Cityblock leverages technology to offer personalized, prevention-oriented care for urban residents with complex health needs. The company's platform facilitates access to preventive visits, mental health services, and social support programs. Additionally, Cityblock offers a communication tool called Commons, which enhances information sharing and task management among members and care teams. During the COVID-19 pandemic, Cityblock developed a model to identify individuals at high risk, highlighting its commitment to addressing urgent health challenges. By prioritizing upstream investments in health and social care, Cityblock aims to improve health outcomes while reducing overall costs.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Attentive Mobile, Inc. is a personalized mobile messaging platform that enables companies to effectively acquire, retain, and engage with their mobile audiences. Founded in 2016 and headquartered in New York, the company serves a diverse range of industries, including e-commerce, retail, food and beverage, travel, hospitality, entertainment, media, publishing, education, and non-profit sectors. By leveraging real-time behavioral data, Attentive automates the delivery of tailored text messages throughout the customer lifecycle, which includes product recommendations, special promotions, payment notifications, and real-time customer service. With over 2,000 clients, including well-known brands like Sephora and Urban Outfitters, Attentive has demonstrated significant effectiveness, achieving impressive metrics such as over 30% click-through rates and more than 25 times return on investment.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Prove provides a phone-centric identity platform designed to enhance security and reduce fraud through the use of phone numbers. With over 1 billion identity tokens under management, Prove assists more than 1,000 companies and over 500 banks, including leading financial institutions, in securing their customer onboarding, digital services, and payment processes. The company offers two primary solutions: Prove Pre-fill™, which streamlines the onboarding process by authenticating consumer identities and auto-filling verified data, and Fonebook™, which provides a comprehensive identity authentication platform to manage customer phone numbers and create a unified customer view across various channels. Additionally, Prove offers multi-factor authentication options, including SMS and voice OTPs, instant link authentication, mobile authentication through cellular networks, voice biometrics, and app-based push authentication. These features enable secure transactions and enhance the overall customer experience across mobile, desktop, and in-store environments. Prove's services are available in 195 countries, underscoring its global reach in identity verification and fraud mitigation.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.
ACV Auctions, Inc. is a wholesale automotive auction company that operates a mobile platform designed for used-car dealers. Founded in 2014 and headquartered in Buffalo, New York, ACV enables dealers to view, bid on, and purchase car inventory through online auctions. The platform facilitates dealer-to-dealer transactions by allowing users to select desired vehicles and receive alerts on their mobile devices when specific cars become available. Additionally, ACV provides a pricing application for franchise dealers and acts as a closing tool for wholesale buyers to bid on vehicles. This innovative marketplace streamlines the buying and selling process within the automotive industry.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
Away is a modern travel and lifestyle brand. The company is a vertically-integrated company offering beautiful, high-quality luggage at an affordable price point. Away designs special objects for modern travel. It started with luggage, designed with thoughtful features that solve real travel problems—for life. Now all that’s left is the world in front of you and the people you share it with. Because getting Away means getting more out of every trip to come.
Prove provides a phone-centric identity platform designed to enhance security and reduce fraud through the use of phone numbers. With over 1 billion identity tokens under management, Prove assists more than 1,000 companies and over 500 banks, including leading financial institutions, in securing their customer onboarding, digital services, and payment processes. The company offers two primary solutions: Prove Pre-fill™, which streamlines the onboarding process by authenticating consumer identities and auto-filling verified data, and Fonebook™, which provides a comprehensive identity authentication platform to manage customer phone numbers and create a unified customer view across various channels. Additionally, Prove offers multi-factor authentication options, including SMS and voice OTPs, instant link authentication, mobile authentication through cellular networks, voice biometrics, and app-based push authentication. These features enable secure transactions and enhance the overall customer experience across mobile, desktop, and in-store environments. Prove's services are available in 195 countries, underscoring its global reach in identity verification and fraud mitigation.
ezCater, Inc. provides online catering ordering solutions for small start-ups and Fortune 500 companies. Its solutions enable users to order food online for meetings. The company offers ezManage, a catering management platform; and ezOrdering that provides restaurants with means to accept online catering orders on their own website. ezCater, Inc. was founded in 2007 and is based in Boston, Massachusetts. It has an additional office in Denver, Colorado.
Peloton is transforming the fitness landscape by integrating high-quality design with advanced technology to offer live and on-demand fitness classes led by top instructors. Founded in 2012 and headquartered in New York, the company operates an interactive fitness platform that includes two main segments: Connected Fitness Products and Subscription services. Revenue from Connected Fitness Products comes from the sale of its bikes and treadmills, along with accessories, delivery, installation, and extended warranties. The Subscription segment, which generates the majority of the company's revenue, includes monthly fees for connected fitness and digital subscriptions. Peloton's unique approach combines hardware, software, and engaging content, creating a socially connected workout experience that appeals to a wide audience. The company sells its products online and through an expanding network of showrooms, primarily serving customers in North America and select international markets.
ezCater, Inc. provides online catering ordering solutions for small start-ups and Fortune 500 companies. Its solutions enable users to order food online for meetings. The company offers ezManage, a catering management platform; and ezOrdering that provides restaurants with means to accept online catering orders on their own website. ezCater, Inc. was founded in 2007 and is based in Boston, Massachusetts. It has an additional office in Denver, Colorado.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Compass is a real estate brokerage company based in New York City, founded in 2012 by Ori Allon, Robert Reffkin, and Ugo Di Girolamo. The company offers a comprehensive platform for residential real estate agents, equipping them with a suite of cloud-based software tailored for customer relationship management, marketing, and client service. This integrated approach enhances the ability of agents to provide exceptional service to buyers and sellers. In addition to its brokerage services, Compass has developed a mobile app for iOS and Android that facilitates buying, selling, and renting homes across the United States. The company operates primarily within the domestic market.
WeWork, known as The We Company, is a commercial real estate firm that specializes in providing flexible workspaces and office services primarily for entrepreneurs and technology startups. Founded in 2010 and headquartered in New York, the company transforms buildings into dynamic environments that foster creativity, collaboration, and productivity. Its offerings include a variety of workplace solutions such as private offices, shared workspaces, and on-demand access to workstations, catering to diverse member needs. In addition to physical spaces, WeWork provides a range of services through partnerships, enabling members to work, live, and grow. The company also operates WeWork Labs, which supports early-stage startups by providing community and programming to aid their development. With a focus on inclusivity and community, WeWork aims to create an environment where members can thrive and innovate together.
Vets First Choice provides veterinary practices with an online pharmacy and home delivery services. It partners with veterinarians to create insight into gaps in patient care and offer professionalized pro-active prescription management to drive client engagement and improve compliance. The company was founded by Ben Shaw in 2010 and is based in Portland, Maine.
Peloton is transforming the fitness landscape by integrating high-quality design with advanced technology to offer live and on-demand fitness classes led by top instructors. Founded in 2012 and headquartered in New York, the company operates an interactive fitness platform that includes two main segments: Connected Fitness Products and Subscription services. Revenue from Connected Fitness Products comes from the sale of its bikes and treadmills, along with accessories, delivery, installation, and extended warranties. The Subscription segment, which generates the majority of the company's revenue, includes monthly fees for connected fitness and digital subscriptions. Peloton's unique approach combines hardware, software, and engaging content, creating a socially connected workout experience that appeals to a wide audience. The company sells its products online and through an expanding network of showrooms, primarily serving customers in North America and select international markets.
Fuze is a cloud-based unified communications platform that enhances productivity and collaboration within organizations. It offers tools for simplified voice communications, flexible video conferencing, and continuous collaboration, allowing modern, mobile workforces to communicate seamlessly across various devices. Fuze’s platform aggregates data from multiple sources, providing valuable insights that help business leaders understand and improve their operations and workforce dynamics. Founded in 2002 and originally known as ThinkingPhones, Fuze is headquartered in Boston, Massachusetts, with additional offices in various global cities, including New York, San Francisco, and London. The company serves a diverse clientele, including well-known organizations such as CareerBuilder, Fujitsu, and Oregon Health & Sciences University.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Defy Media, Inc. specializes in creating and distributing digital content targeted at millennials, particularly in the realms of comedy, entertainment, gaming, and lifestyle. Formed from the merger of Alloy Digital and Break Media, the company has established itself as a significant player in the digital media landscape, producing influential programming for consumers aged 13 to 34. With a strong portfolio of popular brands and effective production, distribution, and marketing capabilities, Defy Media engages its audience across over 25 video platforms, including subscription video on demand (SVOD), television, and film. Incorporated in 2011 and based in New York, Defy Media was previously known as Alloy Digital before rebranding in 2013. It operates as a subsidiary of Alloy, Inc.
Compass is a real estate brokerage company based in New York City, founded in 2012 by Ori Allon, Robert Reffkin, and Ugo Di Girolamo. The company offers a comprehensive platform for residential real estate agents, equipping them with a suite of cloud-based software tailored for customer relationship management, marketing, and client service. This integrated approach enhances the ability of agents to provide exceptional service to buyers and sellers. In addition to its brokerage services, Compass has developed a mobile app for iOS and Android that facilitates buying, selling, and renting homes across the United States. The company operates primarily within the domestic market.
Sprinklr, Inc. is a provider of enterprise software focused on customer experience management, designed to assist brands in managing conversations across various digital channels, including social media and review sites. Founded in 2009 and headquartered in New York, the company offers a comprehensive social software platform that includes tools for content planning, social campaign management, customer relationship management, and analytics. Sprinklr's integrated system supports global brands in optimizing their social media marketing, customer care, and engagement strategies, enabling them to gather insights that inform product development and mitigate potential crises. The company's solutions cater to diverse industries, including technology, automotive, and retail, and it has established partnerships with major organizations like Deloitte Digital. Sprinklr operates internationally, serving over 1,200 enterprise clients and employing more than 1,300 individuals worldwide.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
BEGiN is an education technology company focused on creating engaging learning products for young children. It aims to enhance early childhood education by offering a library of interactive stories designed to foster a love for reading while developing essential skills. The company has established partnerships with notable children's brands such as Sesame Workshop, LEGO Ventures, Gymboree Play and Music, and Fisher-Price, further enriching its educational offerings. Co-founded by Neal Shenoy, Noelle Millholt, and Stephanie Dua, BEGiN has received recognition as one of Crain’s 100 Best Places to Work in New York City. Its flagship product, Speakaboos, provides a reading application that features bedtime stories, nursery rhymes, and songs, contributing to its mission of delivering high-quality education to children everywhere.
BEGiN is an education technology company focused on creating engaging learning products for young children. It aims to enhance early childhood education by offering a library of interactive stories designed to foster a love for reading while developing essential skills. The company has established partnerships with notable children's brands such as Sesame Workshop, LEGO Ventures, Gymboree Play and Music, and Fisher-Price, further enriching its educational offerings. Co-founded by Neal Shenoy, Noelle Millholt, and Stephanie Dua, BEGiN has received recognition as one of Crain’s 100 Best Places to Work in New York City. Its flagship product, Speakaboos, provides a reading application that features bedtime stories, nursery rhymes, and songs, contributing to its mission of delivering high-quality education to children everywhere.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
General Assembly provides education and career transformation, specializing in today’s most in-demand skills. The leading source for training, staffing, and career transitions, we foster a flourishing community of professionals pursuing careers they love.
It was founded in 2011 and headquartered in New York, United States.
Rubicon Global Holdings LLC is a technology company that specializes in cloud-based waste and recycling solutions for businesses, governments, and nonprofits. Founded in 2008 and headquartered in Atlanta, Georgia, Rubicon operates a digital marketplace and offers a suite of software-as-a-service products aimed at enhancing waste management and recycling efforts. The company provides various recycling programs, including services for cardboard, plastic, paper, metal, glass, electronics, and organics, as well as single stream recycling solutions. One of its notable offerings is RUBICONSmartCity, which assists municipal governments in optimizing waste and recycling operations while transforming their fleets into data collection centers to improve quality of life and government services through data analytics. Rubicon serves a global customer base and maintains core teams in several U.S. cities, including New York and San Francisco. The company is committed to driving environmental innovation and helping its partners achieve sustainability goals by finding economic value in waste streams.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Payoneer Inc. operates a cross-border payments platform designed to facilitate global commerce by connecting businesses, professionals, countries, and currencies. Founded in 2005 and headquartered in New York, the company offers products such as the Global Payment Service, which provides users with local receiving accounts in the United States, European Union, and Japan, allowing for direct local bank transfers. Additionally, Payoneer enables users to receive payments from various integrated partners, including those in freelance, e-commerce, and online advertising sectors. The company also provides mass payout services that assist Indian companies in transferring funds internationally. Serving millions of users across over 200 countries, Payoneer is a trusted partner for numerous prominent corporations, making cross-border payments as straightforward as local transactions.
Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.
Harry's, Inc. is a company that specializes in the manufacture and sale of shaving products. Founded in 2012 and headquartered in New York, the company designs and produces its own line of razors, replacement blades, shaving creams, grooming kits, and face care products. Harry's operates primarily through an online platform, offering its products individually or through a subscription model, catering to men's grooming needs. By focusing on quality and convenience, Harry's aims to simplify the shaving experience for consumers.
Warby Parker is a lifestyle brand specializing in the design and sale of vintage-inspired eyeglasses and sunglasses, including prescription glasses and contact lenses. The company aims to provide affordable eyewear while addressing the global issue of vision impairment, as approximately one billion people lack access to affordable glasses. By partnering with experienced non-profit organizations, Warby Parker ensures that each pair of glasses sold helps someone in need obtain eyewear, contributing to improved quality of life and economic opportunities. The company operates through various channels, including physical stores, its website, and mobile applications, offering a range of optical services such as eye exams and vision tests. Revenue is primarily generated from the sale of eyewear products, accessories, and related services.
Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing innovative cancer treatments that harness the immune system to target and eliminate cancer cells. The company's lead product, vopratelimab, is a monoclonal antibody currently in Phase II trials for patients with non-small cell lung cancer and urothelial cancer, particularly those who have not responded to PD-1/PD-L1 inhibitors. Additionally, Jounce is advancing several other therapeutic candidates, including JTX-4014, an anti-PD-1 antibody intended for combination therapy, and JTX-1811, which aims to selectively deplete T regulatory cells in the tumor microenvironment. The company also develops JTX-8064, an antibody targeting a receptor on macrophages. Founded in 2013 by experts in immunobiology and cancer research, Jounce Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to improving patient outcomes through its proprietary immunotherapy platform.
Oscar Health is a health insurance company that provides individual and family plans, Medicare Advantage, and small group products. Founded in 2012 and headquartered in New York, Oscar Health operates in several states, including New York, Texas, California, New Jersey, Ohio, and Tennessee. The company aims to enhance the healthcare experience by utilizing technology, design, and data to create user-friendly services. Its platform includes a software application that helps users find doctors based on location and ratings. Oscar Health primarily serves individuals and families who do not receive health insurance from their employers.
Rethink Robotics is a company based in Boston, Massachusetts, focused on developing advanced robotic solutions for the manufacturing industry. Its flagship product, the Baxter robot, utilizes the Intera software platform to enhance workforce efficiency by integrating trainable, safe, and cost-effective robots alongside skilled human labor. Baxter is designed to automate repetitive and hazardous tasks, such as loading, packing, and inspection, thereby increasing flexibility and reducing operational costs for manufacturers in sectors like automotive, electronics, and consumer goods. Additionally, Rethink Robotics offers the Baxter Research Robot for academic and corporate research, featuring integrated sensors and an open software development kit for custom application development. The company's mission is to drive innovation in robotics and support manufacturers in adapting to the demands of an agile economy. Rethink Robotics is backed by prominent investors, including Bezos Expeditions and Charles River Ventures.
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.
Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Nanigans is a Boston-based company that offers advertising automation software designed for in-house performance marketing teams. Its Software-as-a-Service platform includes features such as programmatic media buying, predictive revenue optimization, and real-time business intelligence. The software enables businesses to identify and remarket to their most valuable customers across various social and mobile channels. In addition to its headquarters in Boston, Nanigans has offices in New York, San Francisco, Seattle, London, Sydney, and Singapore, reflecting its global presence in the advertising technology sector.
Dataminr, Inc. is a real-time information discovery service that specializes in transforming publicly available data into actionable insights for its clients. Founded in 2009 and based in New York, the company employs an AI platform to detect early signs of high-impact events and emerging risks from a diverse array of sources, including social media, blogs, and the dark web. Its flagship product, Dataminr, provides tailored alerts for various sectors, including finance, news, security, and crisis management. For instance, Dataminr for News enables journalists to receive personalized signals based on specific topics and regions, while Dataminr for Finance offers relevant content streams for financial professionals. The platform is adept at identifying critical information related to incidents, threats, and disruptions, empowering businesses to respond promptly to evolving situations such as terrorist threats, social unrest, and extreme weather events. Through its innovative solutions, Dataminr ensures that clients have the necessary information to act confidently in a rapidly changing environment.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
WeWork, known as The We Company, is a commercial real estate firm that specializes in providing flexible workspaces and office services primarily for entrepreneurs and technology startups. Founded in 2010 and headquartered in New York, the company transforms buildings into dynamic environments that foster creativity, collaboration, and productivity. Its offerings include a variety of workplace solutions such as private offices, shared workspaces, and on-demand access to workstations, catering to diverse member needs. In addition to physical spaces, WeWork provides a range of services through partnerships, enabling members to work, live, and grow. The company also operates WeWork Labs, which supports early-stage startups by providing community and programming to aid their development. With a focus on inclusivity and community, WeWork aims to create an environment where members can thrive and innovate together.
Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, most comprehensive solution to improve the security of internally developed, purchased, or outsourced software applications and third-party components. It was founded in 2006 and headquartered in Burlington, Massachusetts.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Lookout is a cybersecurity company that predicts and stops mobile attacks before harm is done to an individual or an enterprise. Lookout’s cloud-based technology is fueled by a global sensor network of more than 60 million users and tens of thousands of apps that are added daily. With this dataset of virtually all the mobile code in the world and the predictive machine intelligence to analyze and make sense of the data, Lookout can identify connections that would otherwise go unseen and stop cybercriminals from attacking mobile devices.
Headquartered in San Francisco, Lookout has offices in Boston, London, Singapore, Tokyo, Toronto and Washington, D.C.
Uber Technologies, Inc. is a technology company that operates a mobile application connecting consumers with independent drivers for ridesharing services, as well as facilitating food delivery through its Eats segment. Founded in 2009 and headquartered in San Francisco, Uber has expanded its operations to over 600 cities worldwide, serving customers across North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company has diversified its offerings into five segments: Rides, Eats, Freight, Other Bets, and Advanced Technologies Group. The Rides segment enables users to request rides from a variety of vehicle types, while the Eats segment allows for restaurant discovery and food delivery. The Freight segment connects carriers with shippers for logistics services. Uber is also focused on developing autonomous vehicle technology through its Advanced Technologies Group. By leveraging its platform, Uber aims to enhance urban mobility and deliver innovative transportation solutions globally.
Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online media companies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
Spark Therapeutics, Inc. is dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. The company is known for LUXTURNA, a treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy, and has an extensive pipeline that includes candidates like SPK-8011 and SPK-8016 for hemophilia, SPK-7001 for choroideremia, and SPK-9001 for hemophilia B. Additionally, Spark is exploring liver-directed gene therapies such as SPK-3006 for Pompe disease and has programs targeting neurodegenerative diseases, including Huntington's disease and a form of Batten disease. Spark Therapeutics also engages in collaborations, notably with Pfizer for the SPK-FIX program for hemophilia B, and has a licensing agreement with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and based in Philadelphia, Spark Therapeutics operates as a subsidiary of Roche Holding AG and leverages a proprietary manufacturing platform to support its clinical studies across various therapeutic areas.
neoSaej's first product is MoneyAisle, a next generation online auction marketplace. Unlike the seller-centric auctions popularized by eBay, MoneyAisle's auctions are buyer-centric: many sellers bid live to win each customer's business. Buyers benefit through great deals by having sellers actively compete for their business in free, safe, instantaneous auctions, on demand, 24/7.
SensAble Technologies, Inc. offers force-feedback haptic devices and touch-enabled 3D modeling software solutions. Its products include FreeForm Modeling Systems, which are 3D touch-enabled systems for medical and dental modeling, product design, digital content creation, and fine arts; and The SensAble Dental Lab System, a digital system for scanning, 3D modeling and design, and 3D fabrication. The company also provides PHANTOM Haptic Devices, which deliver force feedback, 3D navigation, and virtual workspaces; and OpenHaptics, a software development toolkit for developing haptic applications. In addition, it offers 3D touch-enabled modeling systems, software and devices, and 3D modeling software, and sculptural modeling for digital content creation and fine arts. SensAble Technologies serves academic/education, automotive/motorcycle, ceramics, characters and creatures, collectibles/giftware, confectionary, consumer products, dental, engraving, relief and flatware, facial reconstruction, film and video, fine arts and sculpture, footwear, games, home decor and housewares, jewelry, medical, packaging, personal care products, sporting goods, tooling, toys and promotional, assembly path planning, molecular modeling, simulation and visualization, and training industries. The company's products are used in product design, medical and dental modeling, digital content creation, fine arts applications, surgical simulation and stroke rehabilitation, dental restorations, and research and robotic applications. It offers its products through inside sales channels and resellers. The company was founded as SensAble Devices, Inc. in 1993 and changed its name to SensAble Technologies, Inc. in 1996. SensAble Technologies, Inc. is based in Woburn, Massachusetts with a sales office in Tokyo, Japan.